The Breast Cancer Detection Demonstration Project 25 years later

Ca-A Cancer Journal for Clinicians

Volumn 47, Issue 3, 1997, Pages 131-133

  Cunningham, Myles P ^a  

^a St Francis Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TAMOXIFEN;

BREAST CANCER; BREAST EXAMINATION; CANCER SURVIVAL; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; FEMALE; FOLLOW UP; HUMAN; MAMMOGRAPHY; MASS SCREENING; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; SHORT SURVEY;

EID: 0030925166     PISSN: 00079235     EISSN: None     Source Type: Journal    
DOI: 10.3322/canjclin.47.3.131     Document Type: Short Survey

References (15)

1. Report of the working group to review the National Cancer Institute - American Cancer Society Breast Cancer Detection Demonstration Project. J Natl Cancer Inst 1979;62:639-709.
2. National Cancer Institute: Consensus development meeting un breast screening. National Cancer Institute Publication NIH 78-1257. Washington, DC. US Public Health Service. 1977.
3. Smart CA. Byrne CA, Smith RA: Twenty-year follow-up of the breast cancers diagnosed during the Breast Cancer Detection Demonstration Project CA Cancer J Clin 1997;47:134-149.
4. Baines CJ: The Canadian National Breast Screening Study. Why? What next? And so what? Cancer 1995;76 (10 Suppl):2107-2112.
5. Brisson J. Morrison AS, Khalid N: Mammographic parenchymal features and breast cancer in the Breast Cancer Detection Demonstration Project, J Natl Cancer Inst 1988;80:1534-1540.
6. Byrne C. Shairer C. et al: Prospective study of relative weight and breast cancer risk. J Natl Cancer Inst 1995;87:1622-1629.
7. Carter CL., Corle DK, Micozzi et al: A prospective study of the development of breast cancer in women with benign breast disease. Am J Epidemiol 1988;128:467-477.
8. Dupont WD. Parl FF, Hartmann WH. et al: Breast cancer risk associated with proliferative breast disease and atypical hyperplasia. Cancer 1993;71:71:1258-1265.
9. Munoz KA, Ballard-Barbash R, Graubard B, et al: Recall of body weight and both size estimation in women enrolled in the breast cancer detection demonstration project (BCDDP). Int J Obes Relat Metab Disord 1996;20:854-859.
10. Yong LC, Brown CC, Schatzkin A., et al: Prospective study of relative weight and risk of breast cancer. The breast cancer detection demonstration project follow-up study. Am J Epidemiol 1996;143:985-995.
11. Heuser LS, Spratt JS, et al: The association of pathologic and mammographic characteristics of primary human breast cancers with "slow" and "fast" growth rates arid with axillary lymph node metastases Cancer 1984;53:96-98.
12. Goodman MJ: Breast cancer in multi-ethnic populations Breast Cancer Research Treat 1991:18 (Suppl 1):s5-9.
13. Menopausal estrogen replacement therapy and risk of breast cancer. Cancer Causes Control 1994;5:491-500.
14. Sturgeon SR, Schairer C, Brinton LA, et at Evidence of a healthy estrogen user survivor effect. Epidemiology 1995;6:227-231
15. Gail MH, Briton LA, Byar DP, et al: Projecting indivudalized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 1989;81:1879-1886.